Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14806MR)

This product GTTS-WQ14806MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14806MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6552MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ10932MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ8455MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ5728MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ2045MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ3749MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ8077MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ7064MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW